TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27113302
Drug: Solution-focused approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused approach
Study: 25136038
Drug: VIS and
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS and information emphasizing the MMR vaccine's benefits to the child
Study: 22190555
Drug: Remimazolam (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (0.30 mg/kg)
Study: 22190555
Drug: Remimazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (0.05 to 0.20 mg/kg)
Study: 16580903
Drug: Midazolam (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.075 mg/kg)
Study: 22190555
Drug: Remimazolam (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (0.10 and 0.15 mg/kg)
Study: 9311393
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg kg‐1 induction and isoflurane maintenance (Group T/I)
Study: 9311393
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg‐1 induction, 5 mg kg‐1 h‐1 maintenance (Group P5)
Study: 9311393
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg‐1 induction, 10 mg kg‐1 h‐1 maintenance (Group P10)
Study: 30468145
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg daily for 2 weeks, then 30 mg daily for up to 12 months)
Study: 25172798
Drug: Korodin(®) (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korodin(®) (20 drops administered four times with 10 min intervals)
Study: 25172798
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 drops administered four times with 10 min intervals)
Study: 19292893
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone therapy
Study: 15812079
Drug: No menopausal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No menopausal hormone therapy
Study: 14516801
Drug: Patching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching treatment (6 hours per day up to all waking hours)
Study: 9679606
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists and proton pump inhibitors
Study: 9679606
Drug: Drugs for
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for erosions
Study: 1500398
Drug: Flosequinan 50
Normalized name: flosequinan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 50 mg daily for 4 weeks
Study: 28395435
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia and intravenous analgesia (GI)
Study: 23003913
Drug: Immediately Loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately Loaded (IL) DLMF transitional implants
Study: 23003913
Drug: Unloaded (UI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unloaded (UI) DLMF transitional implants
Study: 22225438
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of written and verbal feedback from standardized patients
Study: 18555088
Drug: Enteric-coated mycophenolate-sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate-sodium (EC-MPS) 720 mg b.i.d
Study: 18555088
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg b.i.d
Study: 16018522
Drug: Topical dimethylsulfoxide
Normalized name: Dimethylsulfoxid
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical dimethylsulfoxide (DMSO)
Study: 16018522
Drug: Topical saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical saline (Control)
Study: 6120980
Drug: 100 or
Normalized name: Stalevo 100 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 or 112 microgram of a pili vaccine prepared from Neisseria gonorrhoeae strain F62 in Tris buffer with an aluminum phosphate adjuvant (alum)
Study: 6120980
Drug: 220 microgram
Normalized name: Guaifenesin 20 mg/mL and levomenthol 220 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220 microgram of the F62 pili vaccine prepared in ethanolamine, with or without alum
Study: 22428487
Drug: Ropivacaine 1.5
Normalized name: fentanyl-ropivacaine 1.5 mcg/mL-0.2%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.5 mg ml(-1) plus fentanyl 2 microg ml(-1) (group F)
Study: 22428487
Drug: Ropivacaine 1.5
Normalized name: fentanyl-ropivacaine 1.5 mcg/mL-0.2%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.5 mg ml(-1) plus clonidine 1 microg ml(-1) (group C)
Study: 18533158
Drug: Fat loading
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat loading without treatment
Study: 17874823
Drug: P40 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: P40 tablets (2250 mg/d, 900 mg/d of CoQ10) for 4 weeks
Study: 11277606
Drug: 0.25 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/70 kg triazolam, ingested orally 30 min before bedtime
Study: 3339140
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acyclovir twice a day
Study: 3339140
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acyclovir five times a day for 5 days, then 400 mg three times a day for 1 or 2 months, followed by 400 mg twice a day thereafter
Study: 3339140
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral acyclovir five or six times a day for 5 to 10 days
Study: 25640151
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (CT), n = 76
Study: 17524398
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: M199 + 20% fetal bovine serum (FBS) + 75 mIU/mL recombinant follicle‐stimulating hormone (FSH) + 0.5 IU/mL recombinant hCG
Study: 17524398
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: hCG-free IVM medium (M199 + 20% FBS + 75 mIU/mL recombinant FSH) for 10 hours, then transferred to Group A medium
Study: 15842516
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (IAsp) injected immediately before a meal (0.15 U/kg)
Study: 15842516
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (HI) injected 30 min before a meal (0.15 U/kg)
Study: 10834413
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (HI)
Study: 7128665
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 66 mg noscapine
Study: 7128665
Drug: Oral 150
Normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 150 mg noscapine (rapidly dissolving tablets)
Study: 7128665
Drug: Oral 150
Normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 150 mg noscapine (ion exchange resin-bound tablet)
Study: 26682500
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dapagliflozin and 500 mg metformin XR FDC
Study: 26682500
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dapagliflozin and 1000 mg metformin XR FDC
Study: 26682500
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (individual components of dapagliflozin and metformin XR)
Study: 20524710
Drug: CGA initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CGA initiated drugs
Study: 20524710
Drug: Drugs terminated
Normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs terminated by study physicians
Study: 8974553
Drug: Program to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program to improve recording of drug prescribing
Study: 30810481
Drug: Two-layer wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-layer wound sealing (waterproof topical dressing as first layer and antimicrobial drape as second layer)
Study: 16037177
Drug: Bupivacaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (10 mg)
Study: 24553022
Drug: Bupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine + Sufentanil (7.5 mg + 5 μg)
Study: 20534124
Drug: 4000 IU/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU/week of intravenous epoietin alfa or beta (or equivalent ESA)
Study: 20534124
Drug: 18000 IU/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18000 IU/week of intravenous epoietin alfa or beta (or equivalent ESA)
Study: 15865094
Drug: 5-FU/PSK therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/PSK therapy
Study: 10373231
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 to 10 mg/d)
Study: 10373231
Drug: Cilnidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine (10 to 20 mg/d)
Study: 8675100
Drug: Tauroursodeoxycholate 500
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholate 500 mg/day
Study: 8675100
Drug: Tauroursodeoxycholate 1000
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholate 1000 mg/day
Study: 8675100
Drug: Tauroursodeoxycholate 1500
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholate 1500 mg/day
Study: 8675100
Drug: Tauroursodeoxycholate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholate (all doses)
Study: 8675100
Drug: Tauroursodeoxycholate (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholate (highest dose)
Study: 1378114
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg bemetizide (n = 18)
Study: 1378114
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg bemetizide plus 50 mg triamterene (n = 18)
Study: 1378114
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bemetizide (n = 16)
Study: 1378114
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bemetizide plus 20 mg triamterene (n = 16)
Study: 16639069
Drug: Oral enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enteral nutrition supplement plus supplemental parenteral nutrition (PN+)
Study: 19895595
Drug: Oral enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enteral nutrition supplement (PN-)
Study: 16274150
Drug: Early placement
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early placement of single-tooth acid-etched Osseotite implant (average of 10 days after extraction)
Study: 16274150
Drug: Delayed placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed placement of single-tooth acid-etched Osseotite implant (average of 3 months after extraction)
Study: 12066728
Drug: Dexketoprofen 25
Normalized name: dexketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 25 mg tds for 24 h before and 48 h after surgery
Study: 2684134
Drug: Cognitive-behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural treatment
Study: 9563808
Drug: Non-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-focused treatment
Study: 11755938
Drug: Meals rich
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meals rich in heated safflower oil (60 g)
Study: 11755938
Drug: Meals rich
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meals rich in heated olive oil (60 g)
Study: 9640058
Drug: Pentoxifylline treatment
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline treatment (1200 mg i.v. for the first 5 days, followed by 800 mg orally for subsequent days for 30 days)
Study: 7862232
Drug: Typical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical treatment
Study: 8207318
Drug: Insulin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (100 U/ml) in sterile saline administered twice daily for 8 weeks
Study: 8207318
Drug: Placebo (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile saline) administered twice daily for 8 weeks
Study: 2492464
Drug: Small inspiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small inspiratory resistive load R1 (2.5 cmH2O L/s)
Study: 2492464
Drug: Small inspiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small inspiratory resistive load R2 (5.2 cmH2O L/s)
Study: 1153996
Drug: Drugs that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs that presumably improve the clearance of diseased airways
Study: 31722294
Drug: Custom-made daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom-made daily routine (CDR)
Study: 28225450
Drug: Small incentives
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small incentives for attending timely clinic visits or achieving high medication adherence (US $1.50 awarded through a drawing).
Study: 21483401
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 600 mg or 1200 mg daily for 30 days
Study: 16445786
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate gel
Study: 16445786
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate lotion
Study: 16445786
Drug: BP/erythromycin gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP/erythromycin gel
Study: 16445786
Drug: Erythromycin/zinc solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin/zinc solution
Study: 14740155
Drug: Intraarticular local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular local anaesthetic injection (Bupivacaine)
Study: 9349159
Drug: multizone treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: multizone treatment (62 micrograms, n = 10)
Study: 3713102
Drug: Chronic beta-receptor
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic beta-receptor blockade
Study: 24571603
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure therapy (AAT) for 4 weeks
Study: 22717890
Drug: Carbetocin 80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 80-120 μg
Study: 18772643
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg and hydrochlorothiazide 25 mg (T80/H25)
Study: 18772643
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg and hydrochlorothiazide 12.5 mg (T80/H12.5)
Study: 16033295
Drug: Intravitreous pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreous pegaptanib 0.3 mg
Study: 16033295
Drug: Intravitreous pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreous pegaptanib 0.3-3 mg
Study: 10530259
Drug: Single visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single visit treatment without calcium hydroxide
Study: 10530259
Drug: Single visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single visit treatment with calcium hydroxide
Study: 10530259
Drug: Multivisit treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivisit treatment with calcium hydroxide
Study: 10530259
Drug: Multivisit treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivisit treatment without calcium hydroxide
Study: 8821109
Drug: Shielded 3
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shielded 3 ml safety syringe and components of a needleless IV system
Study: 2149543
Drug: Paracetamol-sobrerol combination
Normalized name: sobrerol
DrugBank: Sobrerol (DB13315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol-sobrerol combination
Study: 7362451
Drug: T3 treatment
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 treatment (200 micrograms/day)
Study: 28916975
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil supplementation (1000 mg n‐3 fatty acid containing 400 mg α‐Linolenic acid)
Study: 21174486
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (5 mg)
Study: 19515734
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g EPA+DHA/d
Study: 19515734
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g EPA+DHA/d
Study: 19515734
Drug: 4.0 g
Normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g high-oleic acid sunflower oil (HOSF)/d
Study: 15234278
Drug: Super blue-green
Normalized name: BLUE GREEN ALGAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super blue-green algae (SBGA) capsules
Study: 7950208
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment of Western medicine (Control)
Study: 1094819
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral isosorbide dinitrate
Study: 21273184
Drug: Clinician-assisted computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-assisted computer-based (CAC) psychological treatment
Study: 1408297
Drug: Therapist-delivered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-delivered treatment
Study: 19296875
Drug: Plant sterol-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol-enriched yoghurt drink (2 g/d)
Study: 19296875
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil n-3 LC-PUFA capsules (2 g/d)
Study: 19296875
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plant sterols and fish oil n-3 LC-PUFA
Study: 19296875
Drug: Control yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control yoghurt drink and control capsules
Study: 11557642
Drug: E(2) administration
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E(2) administration (17beta‐estradiol, transdermal patch, 0.1 mg/day)
Study: 11557642
Drug: E(2) with
Normalized name: E-Z Scrub with Ultradex
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) with P(4) administration (vaginal gel, 90 mg P(4) twice per day)
Study: 3793549
Drug: No radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No radiation therapy
Study: 8614420
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by radiation therapy
Study: 3621549
Drug: Topical dermal
Normalized name: Dermal-Soothe Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dermal anaesthesia (EMLA)
Study: 31237242
Drug: Mindfulness-Based Addiction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Addiction Treatment (MBAT)
Study: 28554988
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder (twice daily for 3 months)
Study: 28554988
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (twice daily for 3 months)
Study: 10473841
Drug: Toluene (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toluene (1.5 mg/min, 4 mg/min), Trichloroethylene (1.5 mg/min, 4 mg/min), n-Hexane (0.3 mg/min, 1.0 mg/min) administered via gastrointestinal application for 60 min.
Study: 1928028
Drug: HIV‐antibody positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐antibody positive cocaine addicts
Study: 29782049
Drug: ADAM zolmitriptan
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADAM zolmitriptan 3.8 mg
Study: 26518044
Drug: Bivalent HPV
Normalized name: HPV, bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent HPV vaccine targeting HPV-16 and HPV-18
Study: 18661867
Drug: Commercial Microcid
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial Microcid immediate-release capsules
Study: 18661867
Drug: Indocap-SR capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indocap-SR capsules
Study: 9459225
Drug: Lidocaine bolus
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine bolus (1.5 mg/kg) and infusion (3 mg/min, unless weight <70 kg, then 2 mg/min)
Study: 2403850
Drug: succinylcholine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 0.15 mg.kg‐1
Study: 2403850
Drug: succinylcholine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 0.25 mg.kg‐1